A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Ku, Hsun Teresa, Ph.D. Research Bookmark and Share

Hsun Teresa Ku, Ph.D. Research

Identification and Characterization of Pancreatic Stem Cells
A functional pancreas consists of two types of tissue: exocrine and endocrine. The exocrine tissue mainly consists of acinar cells, which secrete bicarbonate and digestive enzymes. These secretions are collected by the pancreatic ductal system, which begins with centroacinar cells that are directly in contact with acinar cells. The prolongation of the terminal ducts, or alveoli, are lined by centroacinar cells and gradually merge into a main duct that drains into the duodenum. The endocrine tissue is organized as islets and contains cells that secrete glucagon, insulin, somatostatin, pancreatic polypeptide or grehlin. These endocrine hormones are released directly into the blood stream in response to metabolic signals.
 
Recently, there has been an intense interest in identifying pancreatic stem or progenitor cells, especially the endocrine progenitor cells, for the purpose of replacement therapy of Type 1 diabetes (T1D), a disease in which the insulin-secreting beta cells are specifically destroyed by autoimmunity. However, the existence of self-renewing multipotential stem cells in the pancreas remains elusive. Our laboratory is interested in the identification and characterization of pancreatic stem/progenitor cells, using both mouse models and cadaverous human pancreatic tissues for studies. We have established a quantitative and clonogenic progenitor cell assay in our laboratory, which will be a powerful tool to study the cellular and molecular mechanisms that govern the differentiation and proliferation of the pancreatic stem/progenitor cells at the single cell level.
 
Embryonic Stem Cell Therapy for Type 1 Diabetes
T1D is marked by a deficiency of the insulin-secreting β cells residing in the Islets of Langerhans within the pancreas due to autoimmune destruction. One of the long-term goals of our laboratory is to advance clinical cell-replacement therapy for patients with sever forms of T1D by developing a safe, reliable and abundant source of cells, derived from human stem cells that function like pancreatic islets. Toward this end, we have established an efficient and potentially cost-effective differentiation protocol, originally adapted from a mouse embryonic stem cell (ESC) differentiation method previously established in our laboratory, and generated a population of glucose-responsive, insulin-producing and secreting cells derived from human ESCs while in vitro. This cell population will be a suitable development candidate for clinical cell replacement therapy for T1D at City of Hope in the future.
 
Embryonic Stem Cells as a Cellular Tool for Screening of Molecules for Treatment of Diabetes
In the small molecule drug discovery field, the “bottom-up” approach, which is based on structural considerations of known targets, has not been as fruitful as was once promised. ESC technology ffers a potential solution to this bottleneck. ESCs can be grown in large numbers and maintained in a pluripotent state in vitro. They can also be induced in culture to differentiate into cells from all three germ layers in a relatively normal fashion that is faithful to development in vivo. Three properties make ES cells an ideal platform for drug discovery: first, ES cells can provide virtually inexhaustible quantities of target cells, which is necessary for screening of large numbers of compounds; second, ES cells can differentiate into mature cells with phenotypes that mimic their counterparts in vivo; and third, compared with immortalized cell lines, ES cells and their derivatives will provide a much more accurate platform for the “top-down” drug screening approach. Our laboratory is interested in high throughput screening (HTS) of small molecules that may affect proliferation, differentiation and/or maturation of the pancreatic insulin-producing  β cells and their immediate progenitors. We have established a relatively simple and inexpensive differentiation protocol that allows efficient generation of the pancreatic like, insulin-expressing cells from murine ESCs. Thus, this ESC to pancreatic lineage differentiation assay will be valuable to serve as a cellular tool for screening large number of molecules that could be used to treat diabetes.
 
 
 

H. Teresa Ku, Ph.D. Lab Members

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H. Teresa Ku, Ph.D.
Professor
626-256-HOPE (4673), ext. 61174
 
Jeanne LeBon, Ph.D.
Assistant Research Professor
626-256-HOPE (4673), ext. 63796
 
Dan Gao, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 62251
 
Liang Jin, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 61449
 
Lena Wedeken, Ph.D.,
Postdoctoral Fellow and a CIRM Postdoctoral Scholar
626-256-HOPE (4673), ext. 33242
 
Stephanie Walker, B.S.
Research Associate I
626-256-HOPE (4673), ext. 31235
 
Nadiah Ghazalli, M.S.
Graduate Student and a CIRM Predoctoral Scholar
626-256-HOPE (4673), ext. 31235
 

Ku, Hsun Teresa, Ph.D. Research

Hsun Teresa Ku, Ph.D. Research

Identification and Characterization of Pancreatic Stem Cells
A functional pancreas consists of two types of tissue: exocrine and endocrine. The exocrine tissue mainly consists of acinar cells, which secrete bicarbonate and digestive enzymes. These secretions are collected by the pancreatic ductal system, which begins with centroacinar cells that are directly in contact with acinar cells. The prolongation of the terminal ducts, or alveoli, are lined by centroacinar cells and gradually merge into a main duct that drains into the duodenum. The endocrine tissue is organized as islets and contains cells that secrete glucagon, insulin, somatostatin, pancreatic polypeptide or grehlin. These endocrine hormones are released directly into the blood stream in response to metabolic signals.
 
Recently, there has been an intense interest in identifying pancreatic stem or progenitor cells, especially the endocrine progenitor cells, for the purpose of replacement therapy of Type 1 diabetes (T1D), a disease in which the insulin-secreting beta cells are specifically destroyed by autoimmunity. However, the existence of self-renewing multipotential stem cells in the pancreas remains elusive. Our laboratory is interested in the identification and characterization of pancreatic stem/progenitor cells, using both mouse models and cadaverous human pancreatic tissues for studies. We have established a quantitative and clonogenic progenitor cell assay in our laboratory, which will be a powerful tool to study the cellular and molecular mechanisms that govern the differentiation and proliferation of the pancreatic stem/progenitor cells at the single cell level.
 
Embryonic Stem Cell Therapy for Type 1 Diabetes
T1D is marked by a deficiency of the insulin-secreting β cells residing in the Islets of Langerhans within the pancreas due to autoimmune destruction. One of the long-term goals of our laboratory is to advance clinical cell-replacement therapy for patients with sever forms of T1D by developing a safe, reliable and abundant source of cells, derived from human stem cells that function like pancreatic islets. Toward this end, we have established an efficient and potentially cost-effective differentiation protocol, originally adapted from a mouse embryonic stem cell (ESC) differentiation method previously established in our laboratory, and generated a population of glucose-responsive, insulin-producing and secreting cells derived from human ESCs while in vitro. This cell population will be a suitable development candidate for clinical cell replacement therapy for T1D at City of Hope in the future.
 
Embryonic Stem Cells as a Cellular Tool for Screening of Molecules for Treatment of Diabetes
In the small molecule drug discovery field, the “bottom-up” approach, which is based on structural considerations of known targets, has not been as fruitful as was once promised. ESC technology ffers a potential solution to this bottleneck. ESCs can be grown in large numbers and maintained in a pluripotent state in vitro. They can also be induced in culture to differentiate into cells from all three germ layers in a relatively normal fashion that is faithful to development in vivo. Three properties make ES cells an ideal platform for drug discovery: first, ES cells can provide virtually inexhaustible quantities of target cells, which is necessary for screening of large numbers of compounds; second, ES cells can differentiate into mature cells with phenotypes that mimic their counterparts in vivo; and third, compared with immortalized cell lines, ES cells and their derivatives will provide a much more accurate platform for the “top-down” drug screening approach. Our laboratory is interested in high throughput screening (HTS) of small molecules that may affect proliferation, differentiation and/or maturation of the pancreatic insulin-producing  β cells and their immediate progenitors. We have established a relatively simple and inexpensive differentiation protocol that allows efficient generation of the pancreatic like, insulin-expressing cells from murine ESCs. Thus, this ESC to pancreatic lineage differentiation assay will be valuable to serve as a cellular tool for screening large number of molecules that could be used to treat diabetes.
 
 
 

Lab Members

H. Teresa Ku, Ph.D. Lab Members

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H. Teresa Ku, Ph.D.
Professor
626-256-HOPE (4673), ext. 61174
 
Jeanne LeBon, Ph.D.
Assistant Research Professor
626-256-HOPE (4673), ext. 63796
 
Dan Gao, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 62251
 
Liang Jin, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 61449
 
Lena Wedeken, Ph.D.,
Postdoctoral Fellow and a CIRM Postdoctoral Scholar
626-256-HOPE (4673), ext. 33242
 
Stephanie Walker, B.S.
Research Associate I
626-256-HOPE (4673), ext. 31235
 
Nadiah Ghazalli, M.S.
Graduate Student and a CIRM Predoctoral Scholar
626-256-HOPE (4673), ext. 31235
 
Center for Biomedicine & Genetics
Our Center for Biomedicine & Genetics (CBG) manufactures promising new genetic and cellular agents created by researches for use inclinical trials. We are uniquely equipped to evaluate therapies swiftly and move lifesaving drugs into the marketplace with great speed.
City of Hope has been the home of many illustrious scientists, including six members of the prestigious National Academy of Sciences: Ernest Beutler, Alfred Knudson, Rachmiel Levine, Susumo Ohno, Eugene Roberts, and Arthur Riggs. Learn more about our current scientists and researchers.
Cytogenetics Office Location
City of Hope and Beckman Research Institute 1500 East Duarte Road Duarte, CA 91010-3000 Northwest Building
Room 2265

Phone: 626-256-HOPE (4673), ext. 62025
Fax: 626-301-8877

Biostatistics Office Location
City of Hope and Beckman Research Institute
1500 East Duarte Road
Duarte, CA  91010-3000

Information Sciences Building (#171)

Phone:  626-256-HOPE (4673), Ext. 61444
Fax:  626-471-7106
or 626-301-8802
 
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 


NEWS & UPDATES
  • It was 2009 when a City of Hope patient in her 40s learned that the cancer she had been fighting for several years had metastasized to her lungs. Her medical team ran genetic tests on the tumor, but none of the drug therapies available at the time targeted the known mutations in the tumor cells. […]
  • Acute myeloid leukemia (AML) is characterized by a rapidly-developing cancer in the myeloid line of blood cells, which is responsible for producing red blood cells, platelets and several types of white blood cells called granulocytes. Because AML grows rapidly, it can quickly crowd out normal blood cells, leadi...
  • Rachel Divine is a yoga therapist and patient leader for the Sheri & Les Biller Patient and Family Resource Center. She’s also a former City of Hope patient. When someone you know has cancer, even the word “cancer” can make you feel nervous, sleepless, depressed or more. But, as a yoga teacher for 15 ...
  •   Diagnosed with type 1 diabetes when she was 9 years old, Gina Marchini accepted the fact that she would need insulin the rest of her life. Every day, she injected herself with the lifesaving hormone. She also carefully controlled her diet and monitored the rise and fall of her blood glucose with military...
  • The defeat of cancer will require a team effort. Nowhere is this more necessary (or apparent) than in efforts to combat two of the most deadly forms of the disease  – pancreatic cancer and triple-negative breast cancer. It’s the approach City of Hope is taking with its newly launched multidisciplinary teams, br...
  • It’s a reasonable question: Why is the National Cancer Institute funding a study on preventing heart failure? The answer is reasonable as well: Rates of heart failure are drastically high among childhood cancer survivors — 15 times higher than among people the same age who were never treated for cancer. T...
  • Many teenagers take a break from academics during the summer, but not the eight high school students enrolled in the California Institute for Regenerative Medicine (CIRM) Creativity Awards program at City of Hope. They took the opportunity to obtain as much hands-on research experience as possible, learning fro...
  • About one in eight women will develop breast cancer at some point in her life. In fact, breast cancer is the most common cancer in American women, behind skin cancer. Although women can’t change some risk factors, such as genetics and the natural aging process, there are certain things they can do to lower thei...
  • As genetic testing becomes more sophisticated, doctors and their patients are finding that such tests can lead to the discovery of previously unknown cancer risks. In his practice at City of Hope, Thomas Slavin, M.D., an assistant clinical professor in the Division of Clinical Cancer Genetics, sees the full spe...
  • And the winners are … everyone in the San Gabriel Valley. The recipients of City of Hope’s first-ever Healthy Living grants have been announced, and the future is looking healthier already. In selecting San Gabriel Valley organizations to receive the grants, City of Hope’s Community Benefits Advisory Council ch...
  • Barry Leshowitz is a former City of Hope patient and a family advisor for the Sheri & Les Biller Patient and Family Resource Center. It’s been almost seven years since I checked into a local hospital in Phoenix for a hip replacement, only to be informed by the surgeon that he had canceled the surgery....
  • When it comes to science, the best graduate schools don’t just train scientists, they prepare their students for a lifetime of learning, accomplishment and positive impact on society. At City of Hope, the Irell & Manella Graduate School of Biological Sciences goes one step further – by preparing students to...
  • Cancer affects not just the cancer patient, but everyone around him or her, even after treatment is complete. The challenges can include the fear of cancer recurrence, coping with cancer’s economic impact and the struggle to achieve work-life balance post-treatment. Family members and loved ones of cancer patie...
  •   Bladder cancer facts: Bladder cancer is a disease in which malignant (cancer) cells form in the tissues of the bladder. 2015 estimates: 74,000 new cases of bladder cancer diagnosed 16,000 deaths from bladder cancer (about 11,510 in men and 4,490 in women) Risk factors for bladder cancer: Smoking: Smokers...
  • Women with ovarian cancer have questions about the most promising treatment options, revolutionary research avenues, survivorship and, of course, the potential impact on their personal lives. Now, together in one place, are experts who can provide answers. On Saturday, Sept. 12, the 2015 Ovarian Cancer Survivor...